Prenatal Fish Oil Supplementation, Maternal COX1 Genotype, and Childhood Atopic Dermatitis: A Secondary Analysis of a Randomized Clinical Trial
Eicosanoids have a pathophysiological role in atopic dermatitis (AD), but it is unknown whether this is affected by prenatal ω-3 long-chain polyunsaturated fatty acid (n-3 LCPUFA; ie, fish oil) supplementation and genetic variations in the cyclooxygenase-1 (COX1) pathway. To explore the association...
Saved in:
| Published in: | JAMA dermatology (Chicago, Ill.) Vol. 160; no. 10; p. 1082 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
United States
01.10.2024
|
| Subjects: | |
| ISSN: | 2168-6084, 2168-6084 |
| Online Access: | Get more information |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Eicosanoids have a pathophysiological role in atopic dermatitis (AD), but it is unknown whether this is affected by prenatal ω-3 long-chain polyunsaturated fatty acid (n-3 LCPUFA; ie, fish oil) supplementation and genetic variations in the cyclooxygenase-1 (COX1) pathway.
To explore the association of n-3 LCPUFA supplementation during pregnancy with risk of childhood AD overall and by maternal COX1 genotype.
This prespecified secondary analysis of a randomized clinical trial included mother-child pairs from the Danish Copenhagen Prospective Studies on Asthma in Childhood 2010 birth cohort, with prospective follow-up until children were aged 10 years. In the trial, maternal and child COX1 genotypes were determined, and urinary eicosanoids were quantified when the child was 1 year of age. The present study was conducted from January 2019 to December 2021, and data were analyzed from January to September 2023.
A total of 736 pregnant women at 24 weeks' gestation were randomized 1:1 to 2.4 g of n-3 LCPUFA (fish oil) or placebo (olive oil) per day until 1 week post partum.
Risk of childhood AD until age 10 years overall and by maternal COX1 genotype.
At age 10 years, 635 children (91%; 363 [57%] female) completed the clinical follow-up, and these mother-child pairs were included in this study; 321 (51%) were in the intervention group and 314 (49%) in the control group. Pregnancy n-3 LCPUFA supplementation was associated with lower urinary thromboxane A2 metabolites at age 1 year (β, -0.46; 95% CI, -0.80 to -0.13; P = .006), which was also associated with COX1 rs1330344 genotype (β per C allele, 0.47; 95% CI, 0.20-0.73; P = .001). Although neither n-3 LCPUFA supplementation (hazard ratio [HR], 1.00; 95% CI, 0.76-1.33; P = .97) nor maternal COX1 genotype (HR, 0.94; 95% CI, 0.74-1.19; P = .60) was associated with risk of childhood AD until age 10 years, there was evidence of an interaction between these variables (P < .001 for interaction). Among mothers with the TT genotype, risk of AD was reduced in the n-3 LCPUFA group compared with the placebo group (390 mother-child pairs [61%]; HR, 0.70; 95% CI, 0.50-0.98; P = .04); there was no association for mothers with the CT genotype (209 [33%]; HR, 1.29; 95% CI, 0.79-2.10; P = .31), and risk was increased among offspring of mothers with the CC genotype (37 [6%]; HR, 5.77; 95% CI, 1.63-20.47; P = .007). There was a significant interaction between n-3 LCPUFA supplementation and child COX1 genotype and development of AD (P = .002 for interaction).
In this secondary analysis of a randomized clinical trial, the association of prenatal n-3 LCPUFA supplementation with risk of childhood AD varied by maternal COX1 genotype. The findings could be used to inform a personalized prevention strategy of providing supplementation only to pregnant individuals with the TT genotype.
ClinicalTrials.gov: NCT00798226. |
|---|---|
| AbstractList | Eicosanoids have a pathophysiological role in atopic dermatitis (AD), but it is unknown whether this is affected by prenatal ω-3 long-chain polyunsaturated fatty acid (n-3 LCPUFA; ie, fish oil) supplementation and genetic variations in the cyclooxygenase-1 (COX1) pathway.ImportanceEicosanoids have a pathophysiological role in atopic dermatitis (AD), but it is unknown whether this is affected by prenatal ω-3 long-chain polyunsaturated fatty acid (n-3 LCPUFA; ie, fish oil) supplementation and genetic variations in the cyclooxygenase-1 (COX1) pathway.To explore the association of n-3 LCPUFA supplementation during pregnancy with risk of childhood AD overall and by maternal COX1 genotype.ObjectiveTo explore the association of n-3 LCPUFA supplementation during pregnancy with risk of childhood AD overall and by maternal COX1 genotype.This prespecified secondary analysis of a randomized clinical trial included mother-child pairs from the Danish Copenhagen Prospective Studies on Asthma in Childhood 2010 birth cohort, with prospective follow-up until children were aged 10 years. In the trial, maternal and child COX1 genotypes were determined, and urinary eicosanoids were quantified when the child was 1 year of age. The present study was conducted from January 2019 to December 2021, and data were analyzed from January to September 2023.Design, Setting, and ParticipantsThis prespecified secondary analysis of a randomized clinical trial included mother-child pairs from the Danish Copenhagen Prospective Studies on Asthma in Childhood 2010 birth cohort, with prospective follow-up until children were aged 10 years. In the trial, maternal and child COX1 genotypes were determined, and urinary eicosanoids were quantified when the child was 1 year of age. The present study was conducted from January 2019 to December 2021, and data were analyzed from January to September 2023.A total of 736 pregnant women at 24 weeks' gestation were randomized 1:1 to 2.4 g of n-3 LCPUFA (fish oil) or placebo (olive oil) per day until 1 week post partum.InterventionA total of 736 pregnant women at 24 weeks' gestation were randomized 1:1 to 2.4 g of n-3 LCPUFA (fish oil) or placebo (olive oil) per day until 1 week post partum.Risk of childhood AD until age 10 years overall and by maternal COX1 genotype.Main Outcomes and MeasuresRisk of childhood AD until age 10 years overall and by maternal COX1 genotype.At age 10 years, 635 children (91%; 363 [57%] female) completed the clinical follow-up, and these mother-child pairs were included in this study; 321 (51%) were in the intervention group and 314 (49%) in the control group. Pregnancy n-3 LCPUFA supplementation was associated with lower urinary thromboxane A2 metabolites at age 1 year (β, -0.46; 95% CI, -0.80 to -0.13; P = .006), which was also associated with COX1 rs1330344 genotype (β per C allele, 0.47; 95% CI, 0.20-0.73; P = .001). Although neither n-3 LCPUFA supplementation (hazard ratio [HR], 1.00; 95% CI, 0.76-1.33; P = .97) nor maternal COX1 genotype (HR, 0.94; 95% CI, 0.74-1.19; P = .60) was associated with risk of childhood AD until age 10 years, there was evidence of an interaction between these variables (P < .001 for interaction). Among mothers with the TT genotype, risk of AD was reduced in the n-3 LCPUFA group compared with the placebo group (390 mother-child pairs [61%]; HR, 0.70; 95% CI, 0.50-0.98; P = .04); there was no association for mothers with the CT genotype (209 [33%]; HR, 1.29; 95% CI, 0.79-2.10; P = .31), and risk was increased among offspring of mothers with the CC genotype (37 [6%]; HR, 5.77; 95% CI, 1.63-20.47; P = .007). There was a significant interaction between n-3 LCPUFA supplementation and child COX1 genotype and development of AD (P = .002 for interaction).ResultsAt age 10 years, 635 children (91%; 363 [57%] female) completed the clinical follow-up, and these mother-child pairs were included in this study; 321 (51%) were in the intervention group and 314 (49%) in the control group. Pregnancy n-3 LCPUFA supplementation was associated with lower urinary thromboxane A2 metabolites at age 1 year (β, -0.46; 95% CI, -0.80 to -0.13; P = .006), which was also associated with COX1 rs1330344 genotype (β per C allele, 0.47; 95% CI, 0.20-0.73; P = .001). Although neither n-3 LCPUFA supplementation (hazard ratio [HR], 1.00; 95% CI, 0.76-1.33; P = .97) nor maternal COX1 genotype (HR, 0.94; 95% CI, 0.74-1.19; P = .60) was associated with risk of childhood AD until age 10 years, there was evidence of an interaction between these variables (P < .001 for interaction). Among mothers with the TT genotype, risk of AD was reduced in the n-3 LCPUFA group compared with the placebo group (390 mother-child pairs [61%]; HR, 0.70; 95% CI, 0.50-0.98; P = .04); there was no association for mothers with the CT genotype (209 [33%]; HR, 1.29; 95% CI, 0.79-2.10; P = .31), and risk was increased among offspring of mothers with the CC genotype (37 [6%]; HR, 5.77; 95% CI, 1.63-20.47; P = .007). There was a significant interaction between n-3 LCPUFA supplementation and child COX1 genotype and development of AD (P = .002 for interaction).In this secondary analysis of a randomized clinical trial, the association of prenatal n-3 LCPUFA supplementation with risk of childhood AD varied by maternal COX1 genotype. The findings could be used to inform a personalized prevention strategy of providing supplementation only to pregnant individuals with the TT genotype.Conclusions and RelevanceIn this secondary analysis of a randomized clinical trial, the association of prenatal n-3 LCPUFA supplementation with risk of childhood AD varied by maternal COX1 genotype. The findings could be used to inform a personalized prevention strategy of providing supplementation only to pregnant individuals with the TT genotype.ClinicalTrials.gov: NCT00798226.Trial RegistrationClinicalTrials.gov: NCT00798226. Eicosanoids have a pathophysiological role in atopic dermatitis (AD), but it is unknown whether this is affected by prenatal ω-3 long-chain polyunsaturated fatty acid (n-3 LCPUFA; ie, fish oil) supplementation and genetic variations in the cyclooxygenase-1 (COX1) pathway. To explore the association of n-3 LCPUFA supplementation during pregnancy with risk of childhood AD overall and by maternal COX1 genotype. This prespecified secondary analysis of a randomized clinical trial included mother-child pairs from the Danish Copenhagen Prospective Studies on Asthma in Childhood 2010 birth cohort, with prospective follow-up until children were aged 10 years. In the trial, maternal and child COX1 genotypes were determined, and urinary eicosanoids were quantified when the child was 1 year of age. The present study was conducted from January 2019 to December 2021, and data were analyzed from January to September 2023. A total of 736 pregnant women at 24 weeks' gestation were randomized 1:1 to 2.4 g of n-3 LCPUFA (fish oil) or placebo (olive oil) per day until 1 week post partum. Risk of childhood AD until age 10 years overall and by maternal COX1 genotype. At age 10 years, 635 children (91%; 363 [57%] female) completed the clinical follow-up, and these mother-child pairs were included in this study; 321 (51%) were in the intervention group and 314 (49%) in the control group. Pregnancy n-3 LCPUFA supplementation was associated with lower urinary thromboxane A2 metabolites at age 1 year (β, -0.46; 95% CI, -0.80 to -0.13; P = .006), which was also associated with COX1 rs1330344 genotype (β per C allele, 0.47; 95% CI, 0.20-0.73; P = .001). Although neither n-3 LCPUFA supplementation (hazard ratio [HR], 1.00; 95% CI, 0.76-1.33; P = .97) nor maternal COX1 genotype (HR, 0.94; 95% CI, 0.74-1.19; P = .60) was associated with risk of childhood AD until age 10 years, there was evidence of an interaction between these variables (P < .001 for interaction). Among mothers with the TT genotype, risk of AD was reduced in the n-3 LCPUFA group compared with the placebo group (390 mother-child pairs [61%]; HR, 0.70; 95% CI, 0.50-0.98; P = .04); there was no association for mothers with the CT genotype (209 [33%]; HR, 1.29; 95% CI, 0.79-2.10; P = .31), and risk was increased among offspring of mothers with the CC genotype (37 [6%]; HR, 5.77; 95% CI, 1.63-20.47; P = .007). There was a significant interaction between n-3 LCPUFA supplementation and child COX1 genotype and development of AD (P = .002 for interaction). In this secondary analysis of a randomized clinical trial, the association of prenatal n-3 LCPUFA supplementation with risk of childhood AD varied by maternal COX1 genotype. The findings could be used to inform a personalized prevention strategy of providing supplementation only to pregnant individuals with the TT genotype. ClinicalTrials.gov: NCT00798226. |
| Author | Wang, Tingting Chen, Liang Vahman, Nilo Luo, Yang Ali, Mina Rasmussen, Morten A Lasky-Su, Jessica A Schoos, Ann-Marie M Stokholm, Jakob Bønnelykke, Klaus Kolmert, Johan Ebrahimi, Parvaneh Chawes, Bo Wheelock, Craig E Lovric, Mario Brustad, Nicklas |
| Author_xml | – sequence: 1 givenname: Liang surname: Chen fullname: Chen, Liang organization: Copenhagen Prospective Studies on Asthma in Childhood, Herlev and Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark – sequence: 2 givenname: Nicklas surname: Brustad fullname: Brustad, Nicklas organization: Copenhagen Prospective Studies on Asthma in Childhood, Herlev and Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark – sequence: 3 givenname: Yang surname: Luo fullname: Luo, Yang organization: Copenhagen Prospective Studies on Asthma in Childhood, Herlev and Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark – sequence: 4 givenname: Tingting surname: Wang fullname: Wang, Tingting organization: Copenhagen Prospective Studies on Asthma in Childhood, Herlev and Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark – sequence: 5 givenname: Mina surname: Ali fullname: Ali, Mina organization: Copenhagen Prospective Studies on Asthma in Childhood, Herlev and Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark – sequence: 6 givenname: Parvaneh surname: Ebrahimi fullname: Ebrahimi, Parvaneh organization: Food Microbiology, Gut Health, and Fermentation, Department of Food Science, University of Copenhagen, Frederiksberg C, Denmark – sequence: 7 givenname: Ann-Marie M surname: Schoos fullname: Schoos, Ann-Marie M organization: Department of Pediatrics, Slagelse Hospital, Slagelse, Denmark – sequence: 8 givenname: Nilo surname: Vahman fullname: Vahman, Nilo organization: Copenhagen Prospective Studies on Asthma in Childhood, Herlev and Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark – sequence: 9 givenname: Mario surname: Lovric fullname: Lovric, Mario organization: Faculty of Electrical Engineering, Computer Science and Information Technology Osijek, Josip Juraj Strossmayer University of Osijek, Osijek, Croatia – sequence: 10 givenname: Morten A surname: Rasmussen fullname: Rasmussen, Morten A organization: Food Microbiology, Gut Health, and Fermentation, Department of Food Science, University of Copenhagen, Frederiksberg C, Denmark – sequence: 11 givenname: Johan surname: Kolmert fullname: Kolmert, Johan organization: Unit of Integrative Metabolomics, Institute of Environmental Medicine, Karolinska Institute, Stockholm, Sweden – sequence: 12 givenname: Craig E surname: Wheelock fullname: Wheelock, Craig E organization: Unit of Integrative Metabolomics, Institute of Environmental Medicine, Karolinska Institute, Stockholm, Sweden – sequence: 13 givenname: Jessica A surname: Lasky-Su fullname: Lasky-Su, Jessica A organization: Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts – sequence: 14 givenname: Jakob surname: Stokholm fullname: Stokholm, Jakob organization: Department of Pediatrics, Slagelse Hospital, Slagelse, Denmark – sequence: 15 givenname: Klaus surname: Bønnelykke fullname: Bønnelykke, Klaus organization: Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark – sequence: 16 givenname: Bo surname: Chawes fullname: Chawes, Bo organization: Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/39196551$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkMlOAzEMhiMEYil9BZQjB1qyzJLhVhVakEBFLBK3yjNx1aBMMkzSQ3kJXpkIioQv9uHzJ_s_IfvOOyTkjLMxZ4xfvkMLGvsWordjwUQ2Fiqr9six4IUaFUxl-__mIzIM4Z2lUoxlkh-SI1nxqshzfky-Hnt0EMHSmQlrujCWPm-6zmKLLkI03l3QB4jYu4RMF2-cztH5uO3wgoLTdLo2Vq-913QSfWcaev1zl4kmXNEJfcbGOw39lk6SYBtMoH5FgT6lXd-aT0wGa5xpkv2lN2BPycEKbMDhrg_I6-zmZXo7ul_M76aT-xFIxuOoziXmRSk5VmWlQGkJNVOFlqzSDQjWZFUpBZZC8wJXeaYZqxUCU6JCWa9ADMj5r7fr_ccGQ1y2JjRoLTj0m7BMolLlUgqV0LMduqlb1MuuN236aPkXovgGjoF6Pw |
| CitedBy_id | crossref_primary_10_1016_j_jaad_2025_08_044 |
| ContentType | Journal Article |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1001/jamadermatol.2024.2849 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2168-6084 |
| ExternalDocumentID | 39196551 |
| Genre | Randomized Controlled Trial Journal Article |
| GeographicLocations | Denmark |
| GeographicLocations_xml | – name: Denmark |
| GroupedDBID | 0R~ 4.4 53G AAWTL ABJNI ACGFS ADBBV AENEX AHMBA ALMA_UNASSIGNED_HOLDINGS AMJDE ANMPU BCGUY BRYMA C45 CGR CUY CVF EBD EBS ECM EIF EMOBN EX3 NPM OB3 OBH OGROG OHH OVD PQQKQ RAJ SV3 TEORI WOW 7X8 |
| ID | FETCH-LOGICAL-a301t-b53e56731e9798a8d3ab086d309dca20c49732e72d16ef54d00b8ea0829e3bfa2 |
| IEDL.DBID | 7X8 |
| ISSN | 2168-6084 |
| IngestDate | Sat Nov 01 15:04:16 EDT 2025 Sat Aug 30 01:59:38 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 10 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-a301t-b53e56731e9798a8d3ab086d309dca20c49732e72d16ef54d00b8ea0829e3bfa2 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
| PMID | 39196551 |
| PQID | 3097853328 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_3097853328 pubmed_primary_39196551 |
| PublicationCentury | 2000 |
| PublicationDate | 2024-Oct-01 |
| PublicationDateYYYYMMDD | 2024-10-01 |
| PublicationDate_xml | – month: 10 year: 2024 text: 2024-Oct-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | JAMA dermatology (Chicago, Ill.) |
| PublicationTitleAlternate | JAMA Dermatol |
| PublicationYear | 2024 |
| SSID | ssj0000800431 |
| Score | 2.4484735 |
| Snippet | Eicosanoids have a pathophysiological role in atopic dermatitis (AD), but it is unknown whether this is affected by prenatal ω-3 long-chain polyunsaturated... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 1082 |
| SubjectTerms | Adult Child Cyclooxygenase 1 - genetics Denmark - epidemiology Dermatitis, Atopic - genetics Dermatitis, Atopic - prevention & control Dietary Supplements Fatty Acids, Omega-3 - administration & dosage Female Fish Oils - administration & dosage Follow-Up Studies Genotype Humans Infant Male Pregnancy Prenatal Exposure Delayed Effects - prevention & control Prospective Studies |
| Title | Prenatal Fish Oil Supplementation, Maternal COX1 Genotype, and Childhood Atopic Dermatitis: A Secondary Analysis of a Randomized Clinical Trial |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/39196551 https://www.proquest.com/docview/3097853328 |
| Volume | 160 |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LT9wwELZKqSoutFBeLa0GiSOGJHYSu5dqBaVcdllRKu1t5ae0UpssuwsS_In-5c4kWbihSlxyc-SM7cnneXwfY4dGeBFynXBfas9lTAW3COu5zKLOY4y6cLYRmygHAzUa6WEXcJt3ZZVLn9g4al87ipGfCGo4QGySqW_TG06qUZRd7SQ0VtiqQChDJV3lSD3GWAgNyUaSMEsLxYtEyWWTcEc85Mn9LWrKQWTyGF31M0iz-eOcv3vpXN-z9Q5rQq_dHBvsVag22dt-l03_wP4OZ6Gi8A2QADpcTn5DI_LZFpTTih1B37Qs0XB6OUrhR6hqCtoegak8PNIiQ29RTycOzkILgCfzr9CDn3TX9mZ2D0vmE6gjGLjCsfWfyUPAN3R9mXBN52CL_Tr_fn16wTuBBm7QLyy4zXGdi1KkQZdaGeWFsXhF8vj93pkscZK4gEKZ-bQIMZc-SawKhtp5g7DRZNvsdVVXYZeBik5rJ_I0IEKzmcVrDtrQSlk6E61K9tjB0tRjPACU1TBVqG_n4ydj77Gddr3G05apYyw0ESbm6cf_GP2JrdEmaAv19tlqxOMfPrM37g6tNvvS7Cx8Dob9f8Ol2ZI |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Prenatal+Fish+Oil+Supplementation%2C+Maternal+COX1+Genotype%2C+and+Childhood+Atopic+Dermatitis%3A+A+Secondary+Analysis+of+a+Randomized+Clinical+Trial&rft.jtitle=JAMA+dermatology+%28Chicago%2C+Ill.%29&rft.au=Chen%2C+Liang&rft.au=Brustad%2C+Nicklas&rft.au=Luo%2C+Yang&rft.au=Wang%2C+Tingting&rft.date=2024-10-01&rft.eissn=2168-6084&rft.volume=160&rft.issue=10&rft.spage=1082&rft_id=info:doi/10.1001%2Fjamadermatol.2024.2849&rft_id=info%3Apmid%2F39196551&rft_id=info%3Apmid%2F39196551&rft.externalDocID=39196551 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2168-6084&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2168-6084&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2168-6084&client=summon |